Since 2004, a wealth of new research has produced a deluge
of oncology drugs in development and human trials; more than 900 are being tested today.
Read more... The impact
of oncology drug development - part one - 21/03/13 In the first of our occasional series, we look at how recent oncology drug advances have had an impact on global skills and recruitment trends.
«In recent years, there have been a
number of oncology drugs that have been touted as potential blockbusters, but most haven't sold as well as expected.
Given the role of Msi in promoting aggressive disease, the investigators partnered with Robert MacLeod PhD,
vice-president of oncology drug discovery at Ionis Pharmaceuticals, to develop next - generation antisense oligonucleotide (ASO) inhibitors against Msi.
Perhaps the current
success of oncology drug approvals in the USA will encourage an increased job market within multinational pharmaceutical companies.